Universities Buy Into The Patent Chase

For being at the right place at the wrong time, Bernard Erlanger missed the road to riches back in 1957. The Columbia University microbiologist knew that he had helped pioneer a powerful technique for making antibodies to steroids, and he even suspected that it might have commercial applications. Indeed, the method is now commonly used for everything from controlling animal litter size to testing human hormonal disorders—and the paper Erlanger wrote has become one of the most cited in his

| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

For being at the right place at the wrong time, Bernard Erlanger missed the road to riches back in 1957. The Columbia University microbiologist knew that he had helped pioneer a powerful technique for making antibodies to steroids, and he even suspected that it might have commercial applications. Indeed, the method is now commonly used for everything from controlling animal litter size to testing human hormonal disorders—and the paper Erlanger wrote has become one of the most cited in history.

At the time, a company was anxious to pursue the method’s possibilities, but it wouldn’t proceed without a guarantee of exclusivity. And when the microbiologist and his three colleagues approached the dean of Columbia’s medical school about patenting the discovery, the notion was quickly squelched. “The dean said, ‘No, this is unethical. Biomedical material should not be patented,”’ sighs Erlanger.

“We chuckle and say ‘Boy, just think if the dean ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Robert Buderi

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo